Bio-Techne Corporation

NasdaqGS TECH

Bio-Techne Corporation Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 187.54 M

Bio-Techne Corporation Cash and Short-Term Investments is USD 187.54 M for the quarter ending September 30, 2024, a 26.15% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Bio-Techne Corporation Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 148.66 M, a -26.79% change year over year.
  • Bio-Techne Corporation Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 203.07 M, a -13.61% change year over year.
  • Bio-Techne Corporation Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 235.06 M, a -18.21% change year over year.
  • Bio-Techne Corporation Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 287.39 M, a 81.42% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
NasdaqGS: TECH

Bio-Techne Corporation

CEO Mr. Kim Kelderman
IPO Date Feb. 9, 1989
Location United States
Headquarters 614 McKinley Place N.E.
Employees 3,100
Sector Healthcare
Industries
Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Similar companies

LQDA

Liquidia Corporation

USD 14.23

-1.25%

LEGN

Legend Biotech Corporation

USD 38.10

2.36%

UTHR

United Therapeutics Corporation

USD 351.17

-0.32%

VTYX

Ventyx Biosciences, Inc.

USD 2.01

-1.95%

AKRO

Akero Therapeutics, Inc.

USD 54.08

-2.31%

APLS

Apellis Pharmaceuticals, Inc.

USD 29.01

-4.54%

PCVX

Vaxcyte, Inc.

USD 88.32

-3.95%

ASND

Ascendis Pharma A/S

USD 130.66

2.64%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 271.31

-2.11%

EXEL

Exelixis, Inc.

USD 33.15

0.67%

BMRN

BioMarin Pharmaceutical Inc.

USD 63.36

-0.81%

TVTX

Travere Therapeutics, Inc.

USD 20.46

-2.80%

HALO

Halozyme Therapeutics, Inc.

USD 56.64

0.39%

BPMC

Blueprint Medicines Corporation

USD 112.53

-1.33%

REPL

Replimune Group, Inc.

USD 13.98

2.64%

NUVL

Nuvalent, Inc.

USD 85.81

-2.21%

StockViz Staff

February 4, 2025

Any question? Send us an email